Science at the Frontier
Deep dives into epigenetic reprogramming, longevity science policy, and the future of human lifespan.
The State of Partial Epigenetic Reprogramming in 2024
A comprehensive review of where the field stands — from Sinclair's pioneering work to Altos Labs, and what distinguishes our approach at EpochRevive.
OSKM: What Are Yamanaka Factors and Why Do They Matter?
A deep but accessible explanation of how four transcription factors reshaped our understanding of cellular identity — and opened the door to biological age reversal.
How Epigenetic Clocks Measure Your True Biological Age
Horvath, GrimAge, PhenoAge — a breakdown of the major methylation-based clocks and how they're transforming longevity research from a qualitative art into a quantitative science.
What Is Longevity Escape Velocity — And Can We Actually Achieve It?
de Grey's concept, revisited. With the pace of progress in aging biology, we examine whether LEV is a scientific reality or an optimistic abstraction.
Aging Is Not Destiny: The Scientific Case for Treating It as a Disease
From WHO's acceptance of ICD-11 aging codes to the FDA's TAME trial — the scientific and regulatory landscape is shifting. Here's why aging will be treated like any other disease.
Why We Founded EpochRevive
The founding story — the questions that kept us up at night, the science that gave us hope, and the conviction that this is the most important problem we could work on.